A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with ...

UCL-led trial shows adding niraparib to standard therapy reduces tumour growth risk in men with advanced prostate cancer by ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

A drug used to treat type 2 diabetes may also be used to treat prostate cancer. The corresponding study was published in Molecular Cancer. "This is a significant discovery. For the first time, we have ...

A drug used to treat type 2 diabetes may also be effective in slowing the progression of prostate cancer. This is shown by an international study in which researchers at Umeå University, Sweden, have ...

A UCLA study shows that a new treatment combining radioactive drug with radiation therapy could help delay hormone therapy ...

TUPELO — Some avid watchers of football broadcasts have no doubt become aware of a drug called Pluvicto. That’s because commercials touting the relatively new drug were meant to target a large ...

Studies have shown the popular weight loss drugs known as GLP-1 agonists may be helpful for more than just curbing appetite — and new research is looking at their potential impact on cancer risk.

MILAN, Italy — In patients with prostate cancer and cardiovascular disease, degarelix (Firmagon, Ferring Pharmaceuticals) is associated with fewer serious adverse events and less all-cause death ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

GLP-1 receptor agonists (RAs) were associated with a 17% lower overall cancer risk in adults with obesity or overweight, with particularly reduced risks for endometrial, ovarian, and meningioma ...